Hayfin Capital Management Archives

Hayfin Capital Refinances Senior Secured Term Loan Facility for Xeris Biopharma

Biopharmaceutical company Xeris Biopharma entered into an amended and restated senior secured term loan agreement with funds managed by Hayfin Capital Management. The agreement provides Xeris $200 million of capital at close and the ability to draw down another $15.2 million to redeem its outstanding 5% convertible senior notes due 2025.

Ares Management Provides $135MM Refinancing Credit Facilities to ADMA Biologics

ADMA Biologics executed a definitive credit agreement with Ares Management’s credit funds for $135 million in total senior secured credit facilities, including a $72.5 million asset-backed revolving credit facility and a $62.5 million term loan.

December 19, 2023 Adam Grossman | ADMA Biologics | Ares Management | Chris York | Hayfin Capital Management Ian Koplin

Hayfin Capital Management Completes Credit Agreement Amendment with ADMA Biologics

ADMA Biologics, a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, amended the terms of its existing senior credit facility with Hayfin Capital Management, which matures in March 2027.

May 3, 2023 Adam Grossman | ADMA Biologics | Hayfin Capital Management | Howard Rowe Ian Koplin

Hayfin Capital Management Provides $150MM Senior Secured Term Loan Facility to Xeris

Xeris Biopharma Holdings entered into a senior secured term loan agreement with funds managed by Hayfin Capital Management to provide Xeris with up to a total of $150 million of capital.

March 11, 2022 Andrew Merrill | Evercore | Hayfin Capital Management | Steven Pieper | Xeris Biopharma Holdings Ian Koplin

CIT Provides $35.5MM to Finance Vessels for Greenyield Shipping

CIT’s maritime finance business provided $35.5 million to finance four commercial shipping vessels operated by Greenyield Shipping.

December 29, 2021 CIT | Evan Cohen | Greenyield Shipping | Hayfin Capital Management | Stephen Majeski Ian Koplin

Avadim Health Exits Chapter 11 Following Sale to Hayfin Capital Management

Avadim Health, a healthcare and wellness provider, completed a court-approved sale of substantially all its assets to a newly-created company owned by funds managed by Hayfin Capital Management following its Chapter 11 process.

Avadim Health Enters Stalking Horse Sale Agreement with Hayfin Capital Management

Avadim Health agreed to sell its assets and filed voluntary petitions for protection under Chapter 11. Hayfin Capital Management, Avadim’s existing lender, entered into a binding stalking horse purchase agreement and committed to provide certain debtor-in-possession financing.

Hayfin Capital Management Supplies $400MM Debt Financing to Amicus Therapeutics

Hayfin Capital Management executed a $400 million credit facility for Amicus Therapeutics, a biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases.

July 17, 2020 Amicus Therapeutics | Daphne Quimi | Hayfin Capital Management | Howard Rowe | John F. Crowley Phil Neuffer

Hayfin Capital Management Provides MiMedx with $75MM in Debt Financing

Hayfin Capital Management will provide MiMedx with $75 million in debt financing, including a five-year term loan facility in the aggregate principal amount of $50 million and a one-year, delayed draw term loan facility in the aggregate principal amount of $25 million.

Hayfin Supports Crown Lab GlaxoSmithKline Brands Acquisition

Hayfin Capital Management provided debt financing to support Crown Laboratories and Hildred Capital Partners’ acquisition of North American distribution rights of five OTC consumer brands from GlaxoSmithKline.

December 3, 2018 Crown Laboratories | GlaxoSmithKline | Hayfin Capital Management | Hildred Capital Partners Amanda Koprowski

Tag Archives: Hayfin Capital Management